Wave Life Sciences LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
RA Capital Management and affiliated entities have filed an amended Schedule 13D, confirming a 16.8% beneficial ownership in Wave Life Sciences, Inc. following a corporate redomiciliation.
NASDAQ
RA Capital Management reports a 17.1% stake in Wave Life Sciences as the company initiates a redomiciliation to Delaware via a Scheme of Arrangement.
NASDAQ
RA Capital Management and its affiliates have significantly increased their beneficial ownership in Wave Life Sciences Ltd., now holding 17.5% of the common stock after recent open market purchases totaling over $54 million.
NASDAQ
RA Capital Management's beneficial ownership in Wave Life Sciences has been diluted to 13.4% following a recent public equity offering by the issuer.
NASDAQ
RA Capital Management, L.P. and its affiliates filed an amendment to their Schedule 13D, reporting a dilution of their beneficial ownership in Wave Life Sciences Ltd. to 14.6%.